News & Trends

• 042025-06

  Breaking News! China’s First ARB + Thiazide-like Diuretic Combo Hypertension Drug — Fu Li An® Approved for Market!

• 282025-05

  Salubris Obtains Exclusive License for Small Interfering RNA Drug "GW906"

• 272025-05

  Blockbuster! China's First Domestically Developed ARNI Hypertension Drug Xin Chao Tuo (Sacubitril Alisartan Calcium Tablets) Approved for Market

• 302025-04

  Salubris' Novel Hypertension Drug SAL0140 Gained Clinical Trial Approval

• 172025-04

  Salubris' PCSK9 base-editing drug YOLT-101 has received NMPA acceptance for its clinical trial application

• 142025-02

  SAL0140 Clinical Trial Application Accepted by NMPA, Potential Breakthrough in Hypertension Treatment